Difference between revisions of "Mitomycin (Mutamycin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[File:" to "[[:File:")
m
Line 18: Line 18:
 
==Diseases for which is was used==
 
==Diseases for which is was used==
 
*[[Non-small cell lung cancer_-_historical|Non-small cell lung cancer]]
 
*[[Non-small cell lung cancer_-_historical|Non-small cell lung cancer]]
 +
*[[Pancreatic cancer - historical|Pancreatic cancer]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 48: Line 49:
 
[[Category:Head and neck cancer medications]]
 
[[Category:Head and neck cancer medications]]
 
[[Category:Mesothelioma medications]]
 
[[Category:Mesothelioma medications]]
 +
 +
[[Category:Non-small cell lung cancer medications (historic)]]
 +
[[Category:Pancreatic cancer medications (historic)]]
  
 
[[Category:FDA approved in 1981]]
 
[[Category:FDA approved in 1981]]

Revision as of 13:30, 28 April 2022

General information

Class/mechanism: Antibiotic oncologic isolated from Streptomyces caespitosus; inhibits DNA synthesis and induces crosslinking. At higher concentrations, can also inhibit RNA and protein synthesis.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which is was used

Patient drug information

History of changes in FDA indication

  • 8/24/1981: Initial FDA approval

Also known as

  • Generic names: mitomycin-C, MTC
  • Brand names: Lyomit, Mitocin, Mitocyte, Mitosol, Mitozytrex, Mutamycin

References